on Biophytis (EPA:ALBPS)
Biophytis Unveils Promising Obesity Treatment at ECO 2025
Biophytis presented promising results from its OBA program with BIO101 at the European Congress on Obesity (ECO 2025) in Malaga. Dr. Serge Camelo disclosed clinical developments targeting muscle loss in obese patients treated with GLP-1 receptor agonists.
The presentation highlighted that BIO101, when combined with semaglutide, effectively reverses muscle function decline. Preclinical and clinical trials demonstrated that BIO101 aids in reducing fat mass while preserving muscle strength. Additionally, the SARA-INT phase 2 study supported the potential benefits of BIO101 for sarcopenic obese patients.
The phase 2 OBA trial plans to recruit 164 participants and is set to begin in late 2025, dependent on regulatory and financial conditions. Preliminary safety and efficacy results are expected by mid-2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news